President Trump Extends Most Favored Nation Drug Pricing to Every Medicaid Program in America

Summary: This White House release touts prescription drug pricing achievements under the Trump administration, framing it as a historic first. Headline claims: Prescription drug prices reportedly recorded their sharpest annual decline in over 60 years (since 1963), based on Bureau of Labor Statistics CPI data, with declines occurring every month of 2026. Most Favored Nation pricing: 26 major pharmaceutical manufacturers, covering 90% of the branded U.S. drug market, have agreed to align U.S. prices with those paid by comparable developed nations, projected to save Americans over $600 billion. All 50 states, D.C., and Puerto Rico now receive Most Favored Nation drug pricing under Medicaid, projected to save nearly $65 billion in Medicaid drug costs over the next decade. TrumpRx platform: Has delivered over $700 million in savings and covers more than 1,000 branded and generic medications. Highlights specific price drops: GLP-1 drugs (e.g., weight-loss/diabetes medications) now as low as $149/month (down from over $1,000), with Medicare seniors paying $50/month — over 500,000 seniors reportedly saving $216 million collectively. Claims 50–90%+ price cuts on fertility drugs, inhalers, insulin, and cholesterol medications. Manufacturing/supply chain: The same 26 companies have committed roughly $170 billion to U.S.-based manufacturing and R&D, including stocking a Strategic Active Pharmaceutical Ingredients Reserve to reduce dependence on foreign drug supply chains. Note: This is an administration-authored promotional release; while it cites specific outside sources (BLS, news outlets) for some figures, the overall framing and characterization of causation reflect the administration's own perspective rather than independent analysis.